Carl Zeiss Meditec (ETR:AFX) Second Quarter 2024 Results

Key Financial Results

• Revenue: €472.1m (down 6.4% from 2Q 2023).

• Net income: €46.5m (down 25% from 2Q 2023).

• Profit margin: 9.8% (down from 12% in 2Q 2023). The decrease in margin was driven by lower revenue.

• EPS: €0.52 (down from €0.69 in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Carl Zeiss Meditec EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) exceeded analyst estimates by 12%.

Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Germany.

Performance of the German Medical Equipment industry.

The company's shares are down 3.3% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Carl Zeiss Meditec's balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.